Serious adverse events · people with acute HBV infection
1 finding from 1 review
Serious adverse events · people with hereditary haemochromatosis
1 finding from 1 review
Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)
High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).
1 finding from 1 review
Serious adverse events · people with fatigue in peripheral neuropathy
Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with fatigue in Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
80 participants
GRADE not reported
Adverse events ‐ death · adults with common mental disorders
It is very uncertain whether primary‐level worker‐led collaborative care changes adverse events ‐ death compared with usual care (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with COVID‐19
1 finding from 1 review
Primary outcome 3: Adverse events · people with moderate to severe chronic relapsing dyshidrotic eczema on hands
1 finding from 1 review
Intervention not reported
Adverse events (number) · people with necrotising pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in adverse events at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · migrants
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Adverse events:infection · adults with chronic pain
Active stimulation + other intervention may leads to higher adverse events:infection compared with other intervention alone (low certainty).
1 finding from 1 review
Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Alopecia · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Serious adverse events ( · adults with sickle cell disease in a vaso‐occlusive crisis
1 finding from 1 review
Intervention not reported
Adverse events Length of · and
It is very uncertain whether the intervention changes adverse events Length of (very low certainty).
1 finding from 1 review